177 related articles for article (PubMed ID: 30149590)
1. Use of Non-Steroidal Anti-Inflammatory Drugs and Associated Gastroprotection in a Cohort of Workers.
Lallana MJ; Feja C; Aguilar-Palacio I; Malo S; Rabanaque MJ
Int J Environ Res Public Health; 2018 Aug; 15(9):. PubMed ID: 30149590
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study].
Lanas A; Muñoz M; Caballero Correa M; Martínez Jiménez P;
Gastroenterol Hepatol; 2010 Feb; 33(2):80-91. PubMed ID: 19931944
[TBL] [Abstract][Full Text] [Related]
3. Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study.
Warlé-van Herwaarden MF; Koffeman AR; Valkhoff VE; 't Jong GW; Kramers C; Sturkenboom MC; De Smet PA
Br J Clin Pharmacol; 2015 Sep; 80(3):589-98. PubMed ID: 25777983
[TBL] [Abstract][Full Text] [Related]
4. Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs.
Helin-Salmivaara A; Huupponen R; Virtanen A; Lammela J; Klaukka T
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):425-31. PubMed ID: 15952021
[TBL] [Abstract][Full Text] [Related]
5. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
[TBL] [Abstract][Full Text] [Related]
6. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.
Gigante A; Tagarro I
Clin Drug Investig; 2012 Apr; 32(4):221-33. PubMed ID: 22350497
[TBL] [Abstract][Full Text] [Related]
8. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs.
Ibañez-Cuevas V; Lopez-Briz E; Guardiola-Chorro MT;
Pharm World Sci; 2008 Dec; 30(6):947-54. PubMed ID: 18932013
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.
Moore RA; Derry S; Simon LS; Emery P
Pain Pract; 2014 Apr; 14(4):378-95. PubMed ID: 23941628
[TBL] [Abstract][Full Text] [Related]
11. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.
Sturkenboom MC; Burke TA; Tangelder MJ; Dieleman JP; Walton S; Goldstein JL
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1137-47. PubMed ID: 14653834
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal symptoms in NSAID users in an 'average risk population': results of a large population-based study in randomly selected Dutch inhabitants.
Tielemans MM; van Rossum LG; Eikendal T; Focks JJ; Laheij RJ; Jansen JB; van Oijen MG
Int J Clin Pract; 2014 Apr; 68(4):512-9. PubMed ID: 24499203
[TBL] [Abstract][Full Text] [Related]
13. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.
Valkhoff VE; van Soest EM; Masclee GM; de Bie S; Mazzaglia G; Molokhia M; Kuipers EJ; Sturkenboom MC
Aliment Pharmacol Ther; 2012 Oct; 36(8):790-9. PubMed ID: 22928490
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
15. Reducing NSAID-induced gastrointestinal complications.
Drug Ther Bull; 2011 Feb; 49(2):18-21; quiz i-ii. PubMed ID: 21304164
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of interventions by community pharmacists to reduce risk of gastrointestinal side effects in nonselective nonsteroidal anti-inflammatory drug users.
Teichert M; Griens F; Buijs E; Wensing M; De Smet PA
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):382-9. PubMed ID: 24535837
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotection in NSAID and low-dose aspirin users: a cross-sectional study in primary care.
Lanas A; Plazas MA; Gimeno E; Muñoz-Tudurí M
Gastroenterol Hepatol; 2012 Jan; 35(1):1-7. PubMed ID: 22178503
[TBL] [Abstract][Full Text] [Related]
18. Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in Italy.
Montagnani S; Tuccori M; Testi A; Cristofano M; Corona T; Salvadori S; Scarpignato C; Blandizzi C
Int J Clin Pharm; 2016 Aug; 38(4):829-37. PubMed ID: 27003828
[TBL] [Abstract][Full Text] [Related]
19. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users.
Abraham NS; Hartman C; Castillo D; Richardson P; Smalley W
Am J Gastroenterol; 2008 Feb; 103(2):323-32. PubMed ID: 18289200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
